华泰联合证券有限责任公司 关于江苏东星智慧医疗科技股份有限公司 部分首次公开发行前已发行股份及首次公开发行战略配售股份 上市流通的核查意见 华泰联合证券有限责任公司（以下简称"华泰联合证券"、"保荐机构"） 作为江苏东星智慧医疗科技股份有限公司（以下简称"东星医疗"、"公司"） 首次公开发行股票并在创业板上市持续督导阶段的保荐机构，根据《证券发行 上市保荐业务管理办法》《深圳证券交易所创业板股票上市规则》《深圳证券 交易所上市公司自律监管指第2号——创业板上市公司规范运作》《深圳证券交 易所上市公司自律监管指引第13号——保荐业务》等文件的要求，对东星医疗 部分首次公开发行前已发行股份及首次公开发行战略配售股份上市流通事项进 行了审慎核查，并出具核查意见如下： 一、公司股票发行和股本情况 根据中国证券监督管理委员会《关于同意江苏东星智慧医疗科技股份有限 公司首次公开发行股票注册的批复》（证监许可[2022]1922号），公司首次公 开发行人民币普通股（A股）股票25,043,334股，并于2022年11月30日在深圳证 券交易所创业板上市。首次公开发行股票完成后公司总股本为100,173,334股， 其中有流 ...

证券代码：301290 证券简称：东星医疗 公告编号：2023-070 特别提示： 1、本次解除限售的股份为江苏东星智慧医疗科技股份有限公司（以下简称 "公司"）部分首次公开发行前已发行股份及首次公开发行战略配售股份； 2、本次解除限售的股东户数为 107 户，解除限售股份数量为 44,096,110 股， 占公司总股本的 44.0198%。其中首次公开发行前已发行股份解除限售的股东数 量为 106 户，股份数量为 42,962,066 股，占公司总股本的 42.8877%；首次公开 发行战略配售股份解除限售的股东数量为 1 户，股份数量为 1,134,044 股，占公 司总股本的 1.1321%。限售期为自公司股票首次公开发行并上市之日起 12 个月。 本次解除限售后实际可上市流通数量为 44,088,610 股，占公司总股本的 44.0123%； 3、本次限售股上市流通日为 2023 年 12 月 1 日（星期五）。 一、公司股票发行和股本情况 根据中国证券监督管理委员会《关于同意江苏东星智慧医疗科技股份有限公 司首次公开发行股票注册的批复》（证监许可[2022]1922 号），公司首次公开发 行人民币普 ...

二、监事会会议审议情况 与会监事经过审议，表决通过了以下议案： （一）审议通过《关于选举公司第三届监事会主席的议案》 经审议，监事会同意选举朱慧玲女士为公司第三届监事会主席，任期自本次 监事会审议通过之日起至第三届监事会任期届满之日止。 江苏东星智慧医疗科技股份有限公司 第三届监事会第十三次会议决议公告 一、监事会会议召开情况 证券代码：301290 证券简称：东星医疗 公告编号：2023-068 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 江苏东星智慧医疗科技股份有限公司（以下简称"公司"）第三届监事会 第十三次会议于 2023 年 11 月 1 日在公司会议室以现场方式召开。本次会议通知 已于 2023 年 10 月 27 日通过邮件的方式送达全体监事。经与会监事一致推举， 本次监事会由监事朱慧玲女士召集并主持，会议应出席监事 3 人，实际出席监事 3 人。公司董事会秘书列席会议。本次会议的召开符合有关法律、行政法规、部 门规章、规范性文件和《公司章程》的规定。 特此公告。 江苏东星智慧医疗科技股份有限公司监事会 2023 年 11 月 1 日 表决结 ...

证券代码：301290 证券简称：东星医疗 公告编号：2023-069 江苏东星智慧医疗科技股份有限公司 关于职工代表监事、监事会主席辞职 暨补选职工代表监事、监事会主席的公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、职工代表监事、监事会主席辞职的情况 江苏东星智慧医疗科技股份有限公司（以下简称"公司"）于近日收到职工 代表监事、监事会主席李妍彦女士提交的书面辞职报告，李妍彦女士因个人原因 申请辞去公司第三届监事会职工代表监事、监事会主席职务，辞去上述职务后李 妍彦女士不再担任公司其他任何职务。李妍彦女士原定任期为 2021 年 6 月 29 日至 2024 年 6 月 28 日。 截至本公告披露日，李妍彦女士未直接持有公司股份，其通过常州凯洲投资 管理有限公司间接持有公司股份 4,000 股，持有比例为 0.0040%。李妍彦女士辞 去上述职务后，仍严格遵守《深圳证券交易所上市公司股东及董事、监事、高级 管理人员减持股份实施细则》等相关规定。 李妍彦女士在担任公司职工代表监事、监事会主席期间恪尽职守、勤勉尽责， 为公司经营发展、规范运作发挥了积极 ...

Revenue and Profit - Revenue for Q3 2023 was CNY 109,316,534.77, an increase of 3.37% year-over-year, while year-to-date revenue decreased by 2.08% to CNY 311,118,638.38[5] - Net profit attributable to shareholders for Q3 2023 was CNY 21,377,754.66, down 13.28% year-over-year, and year-to-date net profit decreased by 7.23% to CNY 71,412,640.45[5] - Basic earnings per share for Q3 2023 was CNY 0.21, a decrease of 35.33% compared to the same period last year, with year-to-date earnings per share at CNY 0.71, down 30.39%[5] - Total operating revenue for Q3 2023 was CNY 311,118,638.38, a decrease of 2.0% compared to CNY 317,715,861.50 in Q3 2022[19] - Net profit for Q3 2023 was CNY 73,602,344.79, down 5.0% from CNY 77,519,252.60 in Q3 2022[20] - Earnings per share (EPS) for Q3 2023 was CNY 0.71, compared to CNY 1.02 in the same period last year[20] Cash Flow and Financial Position - The company reported a net cash flow from operating activities of CNY 98,344,712.94, an increase of 22.81% year-to-date[5] - Cash inflow from operating activities was CNY 403,263,084.54, an increase of 18.1% from CNY 341,387,358.86 in Q3 2022[22] - The net cash flow from operating activities for Q3 2023 was ¥98,344,712.94, an increase of 22.8% compared to ¥80,079,637.49 in Q3 2022[23] - The total cash outflow from investing activities was ¥1,014,015,008.93, up 31.5% from ¥771,149,119.96 in the same period last year[23] - The net cash flow from investing activities was -¥556,203,244.86, worsening from -¥102,324,633.01 year-over-year[23] - The cash flow from operating activities was impacted by a total cash outflow of ¥304,918,371.60, compared to ¥261,307,721.37 in the previous year[23] Assets and Liabilities - Total assets as of September 30, 2023, were CNY 2,368,395,851.40, a decrease of 0.65% from the end of the previous year[5] - The company's cash and cash equivalents decreased by 47.07% to CNY 588,417,043.52 compared to the beginning of the year[8] - The company's total liabilities decreased to CNY 138,999,277.99 from CNY 180,044,797.30 year-over-year[19] - The total current assets decreased to CNY 1,446,227,017.57 from CNY 1,485,218,174.08, a decline of about 3%[17] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 13,377[11] - The largest shareholder, Wan Shiping, holds 25.01% of the shares, totaling 25,052,934 shares[11] - The company has a significant number of shares held by major shareholders, with 万世平 holding 25,052,934 shares[14] Government Support and Other Income - The company received government subsidies amounting to CNY 408,480.35 during the reporting period, mainly from tax rewards and listing incentives[6] - Other income rose by 118.57% to 13,100,464.28 CNY primarily from government subsidies received[9] - Cash received from tax refunds increased by 194.36% to 6,873,344.86 CNY due to higher tax refund amounts[10] - Cash received from other operating activities rose by 197.34% to 24,345,622.49 CNY, mainly from government subsidies and bank interest[10] Expenses and Financial Performance - Total operating costs increased to CNY 250,384,360.50, up 5.0% from CNY 236,611,808.79 in the previous year[19] - Research and development expenses for the period were CNY 20,237,381.58, up from CNY 18,398,015.50 in the previous year[19] - Financial expenses increased by 2,698.03% to -8,824,150.92 CNY due to increased bank deposit interest income[9] - The company reported a financial income of CNY 8,981,112.92, compared to CNY 148,144.89 in the previous year[19] Strategic Focus and Future Plans - The company plans to maintain its strategic focus on expanding its market presence and developing new technologies[16] - The company has a scheduled release of restricted shares for several major shareholders, with dates ranging from November 30, 2023, to May 30, 2026[14] Audit and Accounting Standards - The company did not undergo an audit for the Q3 2023 report[24] - The company has not adopted the new accounting standards for the current year[24]

Financial Performance - The company's operating revenue for the reporting period was ¥201,802,103.61, a decrease of 4.79% compared to ¥211,962,424.90 in the same period last year[23]. - The net profit attributable to shareholders was ¥50,034,885.79, down 4.37% from ¥52,322,704.40 year-on-year[23]. - The net profit after deducting non-recurring gains and losses was ¥32,939,106.31, representing a significant decline of 33.52% compared to ¥49,550,225.12 in the previous year[23]. - The net cash flow from operating activities increased by 24.59% to ¥64,035,419.50, compared to ¥51,397,118.96 in the same period last year[23]. - The total assets at the end of the reporting period were ¥2,339,403,110.47, a decrease of 1.86% from ¥2,383,777,699.00 at the end of the previous year[23]. - The company reported a weighted average return on equity of 2.27%, down from 4.70% in the previous year[23]. - The basic earnings per share decreased by 28.57% to ¥0.50 from ¥0.70 in the same period last year[23]. - The gross margin for the stapler product line was 70.07%, down 5.55% from the previous year[56]. - The company's cash and cash equivalents decreased significantly by 3,159.50% to -¥504,422,303.09, primarily due to increased outflows from investment and financing activities[54]. Research and Development - The company has 25 ongoing research projects, including the development of a self-cleaning laparoscopic puncture device aimed at improving surgical outcomes and reducing contamination[44]. - The company has obtained 37 medical device registration certificates, including 3 Class I and 34 Class II products, and has received multiple international certifications such as FDA and CE[43]. - Research and development investment rose by 15.43% to ¥13,227,443.69, compared to ¥11,459,585.81 in the previous year[54]. - The company is focusing on the design of a new type of vascular stapler, which is expected to fill a gap in the market and enhance brand value[47]. - The company is committed to producing high-quality medical devices with lower production costs, which will facilitate mass production and enhance revenue generation[47]. Market Position and Strategy - The company is focused on the development of high-value medical consumables and advanced medical technologies[15]. - The company has established strong partnerships with major medical device brands and has been a key distributor for Mindray and other brands for over 20 years, enhancing its market position[43]. - The company is actively monitoring and evaluating goodwill impairment risks, particularly in light of potential market fluctuations and policy changes[88]. - The company aims to enhance the quality of its distributor network through improved evaluation and support mechanisms, ensuring the provision of high-quality products and services[86]. - The company plans to continue expanding its market presence and invest in new product development to drive future growth[161]. Compliance and Governance - The company has committed to ensuring the accuracy and completeness of its financial reports, with key personnel affirming their responsibility[3]. - The report outlines the company’s commitment to compliance with regulatory standards, including CE and FDA certifications for its products[15]. - The company has a comprehensive regulatory compliance strategy, including multiple licenses and permits for its medical device production and sales[87]. - The management team emphasizes the importance of risk awareness regarding future plans and forecasts[4]. - The company has not encountered any violations in the use and management of raised funds, ensuring compliance with relevant laws and regulations[68]. Shareholder and Investor Relations - The company plans to not distribute cash dividends or issue bonus shares for the first half of 2023[95]. - The company held two temporary shareholder meetings with investor participation rates of 32.34% and 31.89% respectively[93]. - The company approved the 2023 Restricted Stock Incentive Plan, which aims to enhance sustainable development and protect shareholder interests[96][98]. - The company emphasizes investor rights protection by ensuring timely and accurate information disclosure[102]. - The company has a stable cash dividend policy to maintain shareholder rights, particularly for small and medium investors[102]. Operational Efficiency - The company has established a comprehensive supply chain for surgical staplers, including design, mold development, production, assembly, and inspection, adopting a production model based on customer orders and market demand[35]. - The company maintains a robust procurement strategy, focusing on qualified suppliers and ensuring quality through a comprehensive evaluation process[34]. - The company is focusing on expanding its market presence through innovative product development and strategic enhancements in its existing product lines[45]. - The company is actively engaged in the development of new medical technologies and market expansion strategies[186]. - The company is focusing on optimizing management mechanisms and enhancing collaboration among subsidiaries to improve overall production and R&D efficiency[71]. Financial Management - The total amount of funds raised by the company is RMB 100,257.27 million, with RMB 3,187.64 million utilized during the reporting period[65]. - The company has incurred bank fees of RMB 653.72 million and pending issuance costs of RMB 602,830.18 million[66]. - The company has not reported any changes in its board of directors or senior management during the reporting period[94]. - The company has not engaged in any significant asset or equity acquisitions or disposals during the reporting period[115]. - The company has not experienced any major litigation or arbitration matters during the reporting period[113].

江苏东星智慧医疗科技股份有限公司 2023 年半年度非经营性资金占用及其他关联资金往来情况汇总表 | | | | 占用方与上市公 | 上市公司核算 | 2023 年期初 | 2023 年半年度 占用累计发生 | 2023 年半年 | 2023年半年 | 2023 年半年 | 占用形成 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非经营性资金占用 | 资金占用方名称 | | 司的关联关系 | 的会计科目 | 占用资金余额 | 金额 | 度占用资金的 | 度偿还累计 | 期末占用资 | 原因 | 占用性质 | | | | | | | | （不含利息） | 利息(如有) | 发生金额 | 金余额 | | | | 控股股东、实际控制 | | | | | | | | | | | 非经营性占用 | | 人及其附属企业 | | | | | | | | | | | 非经营性占用 | | 小计 | | - | - | - | | | | | | - | - | | 前控股股东、实际控 | | | | | | | ...

证券代码：301290 证券简称：东星医疗 公告编号：2023-060 江苏东星智慧医疗科技股份有限公司 第三届董事会第十四次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 江苏东星智慧医疗科技股份有限公司（以下简称"公司"）第三届董事会第 十四次会议于 2023 年 8 月 24 日在公司会议室以现场结合通讯的方式召开。本次 会议通知已于 2023 年 8 月 14 日通过邮件的方式送达全体董事。本次会议应出席 董事 7 人，实际出席董事 7 人，其中独立董事费一文、徐光华、蒋海洪以通讯方 式出席会议。会议由董事长万世平先生召集并主持，公司监事、高级管理人员列 席了本次董事会。本次会议的召集、召开和表决程序符合《公司法》等有关法律 法规及《公司章程》的相关规定。 根据深圳证券交易所印发的《深圳证券交易所上市公司自律监管指引第 2 号 ——创业板上市公司规范运作》及相关格式指引的规定，公司董事会编制了《2023 年半年度募集资金存放与使用情况的专项报告》。 经审核，董事会认为：公司 2023 年半年度募集资金存放与使用情况 ...

证券代码：301290 证券简称：东星医疗 公告编号：2023-065 江苏东星智慧医疗科技股份有限公司 一、募集资金基本情况 (一)实际募集资金金额、资金到位情况 经中国证券监督管理委员会证监许可[2022] 1922 号文《关于同意江苏东星智 慧医疗科技股份有限公司首次公开发行股票注册的批复》核准，由主承销商华泰 联合证券有限责任公司向公众投资者发行人民币普通股（A 股）25,043,334 股， 发行价格为每股 44.09 元，募集资金总额为 1,104,160,596.06 元，扣除与发行有关 的费用人民币 101,587,913.35 元（不含税），实际募集资金净额为人民币 1,002,572,682.71 元。上述资金于 2022 年 11 月 25 日全部到位，已经立信会计师 事务所（特殊普通合伙）审验，并于 2022 年 11 月 25 日出具信会师报字[2022] 第 ZA16181 号《验资报告》。 (二)2023 年半年度募集资金使用情况及结余情况 截至 2023 年 6 月 30 日，公司募集资金使用情况如下： 单位：人民币元 | 募集资金账户情况 | 金额 | | --- | --- ...

华泰联合证券有限责任公司 关于江苏东星智慧医疗科技股份有限公司 2023 年半年度跟踪报告 | 保荐人名称：华泰联合证券有限责任公司 | 被保荐公司简称：东星医疗 | | --- | --- | | 保荐代表人姓名：庄晨 | 联系电话：025-83388070 | | 保荐代表人姓名：黄飞 | 联系电话：025-83388070 | 一、保荐工作概述 | 项目 | 工作内容 | | --- | --- | | 1.公司信息披露审阅情况 | - | | （1）是否及时审阅公司信息披露文件 | 是 | | （2）未及时审阅公司信息披露文件的次数 | 0 次 | | 2．督导公司建立健全并有效执行规章制度的情况 | - | | （1）是否督导公司建立健全规章制度（包括 | | | 但不限于防止关联方占用公司资源的制度、 | 是 | | 募集资金管理制度、内控制度、内部审计制 | | | 度、关联交易制度） | | | （2）公司是否有效执行相关规章制度 | 是 | | 3.募集资金监督情况 | - | | （1）查询公司募集资金专户次数 | 每月 次 1 | | （2）公司募集资金项目进展是否与信息披露 | 是 | ...